Europe's ailing drug makers
Article Abstract:
European pharmaceutical companies have tended to be protected by government policies, but this is changing as pressure increases to cut the cost of public health care. The industry is fragmented in Germany and France, in contrast to the US and Britain, where it has undergone consolidation. Many European pharmaceutical companies are reluctant to merge because owners do not want to lose control. Companies need capital from outside in order to develop new drugs, but a stock market launch may not be carried out until the founder departs.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Drugs high
Article Abstract:
The UK's biotechnology industry is is buoyant, with many biotech firms maturing and becoming profitable. However, there are concerns over the impact of legislation on cloning and of protests by animal rights groups.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Science and profit
Article Abstract:
Moral and economic issues related to scientific research, such as research on human genetics, and pharmaceutical research, are examined in detail.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Barak's deadline for peace. Despondency
- Abstracts: Groupe Everest. Taxi Advertising & Design
- Abstracts: Surfing for cheapskates. Care to share? Is the solution also the problem?
- Abstracts: Calming the waters. Future perfect. The swaps emperor's new clothes
- Abstracts: Amalia Rodrigues. Follow this face. The inclusive Mr Adams